UCB, a global biopharmaceutical company, announced plans for a significant investment in a new, state-of-the-art drug ...

The biopharma company—whose US headquarters is in Atlanta—will be building a new biologics manufacturing facility in a city ...

Belgian pharmaceutical company UCB says it plans to invest $5bn in a US factory to avoid President Trump’s tariffs on the EU.

Belgium’s largest drugmaker UCB has announced plans for a significant investment in a new, state-of-the-art biologics ...

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...

Amid the threat of pharmaceutical tariffs from President Donald Trump, recent months have seen multibillion-dollar U.S.

UCB, a global biopharmaceutical company focused on improving the lives of people with severe diseases, today announced plans for a significant investment in a new, state-of-the-art biologics ...

UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus standard care.

The firm will use the funds to further develop its lead genetic medicine in Stargardt disease and advance its gene therapy pipeline in other indications.

DelveInsight's Alzheimer's Disease Pipeline report depicts a robust space with 200+ active players working to develop 220+ ...